title: Mutant presenilin 2 transgenic mice. A large increase in the levels of Abeta 42 is presumably associated with the low density membrane domain that contains decreased levels of glycerophospholipids and sphingomyelin.
abstract: The N141I mutation in presenilin (PS) 2 is tightly linked with a form of autosomal dominant familial Alzheimer's disease in the Volga German families. We previously reported that mouse brains harboring mutant PS2 contained increased levels of amyloid beta protein (Abeta) 42 in the Tris-saline-soluble fraction (Oyama, F., Sawamura, N., Kobayashi, K., Morishima-Kawashima, M., Kuramochi, T., Ito, M., Tomita, T., Maruyama, K., Saido, T. C., Iwatsubo, T., Capell, A., Walter, J., Grünberg, J., Ueyama, Y., Haass, C. and Ihara, Y. (1998) J. Neurochem. 71, 313-322). Here, using a new extraction protocol, we quantitated the Abeta40 and Abeta42 levels in the Tris-saline-insoluble fraction. The insoluble Abeta levels were found to be higher than the soluble Abeta levels, and the insoluble Abeta42 levels were markedly increased in mutant PS2 transgenic mice. To investigate the origin of the insoluble Abeta42, we prepared the detergent-insoluble, low density membrane fraction. This fraction from two independent lines of mutant PS2 transgenic mice contained remarkably increased levels of Abeta42 and significantly low levels of glycerophospholipids and sphingomyelin. This unexpected finding suggests that a large increase in the levels of Abeta42 in mutant PS2 mice is presumably induced through alterations of the lipid composition in the low density membrane domain in the brain.
authors.affiliation: Department of Neuropathology, Faculty of Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Sawamura
authors.forename: M
authors.initials: M
authors.lastname: Morishima-Kawashima
authors.forename: H
authors.initials: H
authors.lastname: Waki
authors.forename: K
authors.initials: K
authors.lastname: Kobayashi
authors.forename: T
authors.initials: T
authors.lastname: Kuramochi
authors.forename: M P
authors.initials: MP
authors.lastname: Frosch
authors.forename: K
authors.initials: K
authors.lastname: Ding
authors.forename: M
authors.initials: M
authors.lastname: Ito
authors.forename: T W
authors.initials: TW
authors.lastname: Kim
authors.forename: R E
authors.initials: RE
authors.lastname: Tanzi
authors.forename: F
authors.initials: F
authors.lastname: Oyama
authors.forename: T
authors.initials: T
authors.lastname: Tabira
authors.forename: S
authors.initials: S
authors.lastname: Ando
authors.forename: Y
authors.initials: Y
authors.lastname: Ihara
mesh_terms: D019943:Amino Acid Substitution; D016229:Amyloid beta-Peptides / Q000378:metabolism*; D000818:Animals; D001921:Brain / Q000378:metabolism*; D001923:Brain Chemistry; D003433:Crosses, Genetic; D005732:Gangliosides / Q000378:metabolism; D020404:Glycerophospholipids / Q000378:metabolism; D006579:Heterozygote; D006801:Humans; D008565:Membrane Proteins / Q000235:genetics* / Q000378:metabolism; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D010446:Peptide Fragments / Q000378:metabolism*; D053766:Presenilin-2; D013109:Sphingomyelins / Q000378:metabolism
chemical_list: D016229:Amyloid beta-Peptides; D005732:Gangliosides; D020404:Glycerophospholipids; D008565:Membrane Proteins; C508861:PSEN2 protein, human; D010446:Peptide Fragments; D053766:Presenilin-2; D013109:Sphingomyelins; C078592:amyloid beta-protein (1-40); C075222:amyloid beta-protein (1-42); C106354:flotillins